RAPID DETECTION OF APOLIPOPROTEIN E GENOTYPES IN ALZHEIMER’S DISEASE USING POLYMERASE CHAIN REACTION-SINGLE STRAND CONFORMATION POLYMORPHISM

Worawan Kamruecha1, Sirintorn Chansirikarnjana2, Ekapot Nimkulrat3, Chesda Udommongkol4, Wanna Wongmek4 and Wipawan Thangnipon1

1Neuro-Behavioural Biology Center, Institute of Science and Technology for Research and Development, Mahidol University, Nakhon Pathom; 2Department of Neurology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok; 3Division of Neurology, Praram 9 Hospital, Bangkok; 4Neurology Unit, Pramongkutklao Hospital, Bangkok, Thailand

Abstract. Apolipoprotein E (APOE) gene on chromosome 19q13.2 is encoded by three common alleles designated as ε2, ε3 and ε4. In Alzheimer’s disease (AD) the ε4 allele is over-represented and is considered to be a major genetic risk factor. Several methods have been developed to determine APOE genotypes. Among them, polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) appears to be highly reliable. In this study, we improved the nonisotopic PCR-SSCP method for determining APOE genotypes in 42 cases of AD patients, 40 cases of non-AD dementia patients, and 49 cases of age-matched controls. DNA from the target sequence on APOE was amplified by PCR from peripheral blood genomic DNA. PCR products were electrophoresed in a non-denaturing polyacrylamide gel and visualized by silver staining. We found that the ε4 allele had a significantly high frequency of occurrence in AD patients (33.3%) compared with age-matched controls (13.3%) (χ² = 10.43, p = 0.001) and non-AD dementia (10%) (χ² = 13.02, p<0.001) whereas the ε3 allele was of high frequency in non-AD dementia (90%) compared with age-matched controls (85.7%) and AD patients (66.7%). APOE ε4 homozygotes were found only in AD groups. On the other hand, the ε2 allele was found only in an age-matched control. This study confirmed that the APOE ε4 allele is a risk factor in Thai AD subjects and that the PCR-SSCP method is a rapid and useful means of detecting the APOE genotype in AD.

INTRODUCTION

Alzheimer’s disease (AD) is the most common form of dementia and is a genetically heterogeneous neurodegenerative disorder that occurs in middle or late life characterized by global cognitive decline and distinct neuropathological hallmarks in the brain. Neuropathologically, the brains of AD patients contain abundant amounts of neurofibrillary tangles and β-amyloid in the form of senile plaques and blood vessel deposit (Hardy, 1997). It is now well-established that some cases of AD, mainly early-onset, show autosomal dominant inheritance patterns due to the presence of mutated genes, including those encoding amyloid precursor protein, presenilin 1 and presenilin 2. However, the late-onset disease, which is more challenging for genetic analysis, has been associated with the presence of apolipoprotein E type 4 (APOE ε4) (Price et al, 1998). The APOE gene encodes a 299 amino acid secreted protein.
There are three major isoforms of ApoE (E2, E3 and E4) that are three products of three allelic forms (ε2, ε3 and ε4) of this single gene locus. Three homozygous phenotypes (ApoE2/E2, E3/E3 and E4/E4) and three heterozygous phenotypes (ApoE3/2, E4/3 and E4/2) arise from the expression of any two of three alleles. The three isoforms differ by interchange of cysteine (Cys) and arginine (Arg) residues at positions 112 and 158 of the mature ApoE. ApoE2 has Cys residues in both of these positions, ApoE3 has Cys-112 and Arg-158, and ApoE4 has Arg in both positions. The presence of APOE ε4 allele has been identified as a major risk factor for both sporadic and late-onset AD (Corder et al, 1993; Saunders et al, 1993; Parker et al, 2005) accounting for about 50% of the genetic risk associated with the late-onset AD (Farrer et al, 1997). It is found in both men and women, but appears to be more predominant in women (Corder et al, 2004).

Several methods have been developed to determine APOE genotypes, eg polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) (Kontula et al, 1990; Hixson and Verneir, 1999; Senanarong et al, 2001) and polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) (Tsai et al, 1993; Wilton and Lim, 1995). The former is commonly used to detect the APOE genotype but it is rather time-consuming and there is an association with incomplete cleavage. The latter method does not require any restriction enzyme and can be used successfully to distinguish the three common APOE alleles that differ from each other by either one or two single-base substitutions. However, PCR-SSCP as previously reported is not very convenient, since it requires radio-labelled primers followed by autoradiography (Orita et al, 1989; Hayashi and Yandell, 1993). In this study we have developed a rapid and nonisotopic PCR-SSCP method for determining the distribution of APOE genotypes in Thai Alzheimer’s patients.

**MATERIALS AND METHODS**

**Subjects**

Subjects were patients from the Department of Neurology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. Written informed consent was obtained from all patients or their primary caregivers. All subjects were diagnosed according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, DSM-IV by American Psychiatric Association, 1994 (Boller and Traykov, 1999). One hundred and thirty-one of subjects were obtained in our study. They were classified into 3 groups: 42 Alzheimer’s patients, 40 non-AD demented patients, and 49 age-matched controls. DNA was extracted from peripheral blood leukocytes using the method of Blin and Stafford (1976).

**PCR-SSCP analysis**

Oligonucleotide primers for amplification of APOE gene were synthesized by ABI Applied Biosystems (Frederick, MD). The sequences were 5’ GGA CAA CTG AGC CCG GTG GCG G 3’ (sense) and 5´ GGA TGG CGC TGA GGC CGC GCT C 3´ (antisense) (Tsai et al, 1993). This set encompasses the sequence from nucleotides 3649-3943 (codons 80-178) and should generate a 295-bp product. The PCR reaction mixture (25 µl) contained 50-100 ng of genomic DNA, 2.5 units of Taq polymerase (Pharmacia Biotech, USA), 1x thermophilic-magnesium free buffer (50 mM KCl, 10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 0.1% Triton X-100, 50 % glycerol), 2.0 mM MgCl₂, 0.2 mM each deoxyribonucleotide triphosphates and 1.0 µM of each primer. The reactions were performed with a Perkin-Elmer 9600 thermal cycler. Amplification cycles were as follows: 30 cycles of denaturation at 95°C for 1 minute, annealing at 65°C for 30 seconds, and extension at 70°C for 75 seconds. This was followed by one cycle of denaturation at 95°C for 1 minute, primer annealing
RAPID DETECTION OF APOLipoprotein E Genotypes in Alzheimer’s Disease

Table 1
APOE genotypes and allele frequencies in Alzheimer’s disease (AD), non-AD dementia (non-AD) and age-matched control subjects.

<table>
<thead>
<tr>
<th>Subject (n)</th>
<th>Median onset age (range)</th>
<th>APOE genotype</th>
<th>APOE allele frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>$\varepsilon 2/\varepsilon 2$</td>
<td>$\varepsilon 2/\varepsilon 3$</td>
</tr>
<tr>
<td>AD (42)</td>
<td>73 (51-93)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>M (18): F (24)</td>
<td></td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Non-AD (40)</td>
<td>72 (53-93)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Control (49)</td>
<td>70 (54-81)</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>M (14): F (35)</td>
<td></td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

M, male; F, female; n, numbers of cases.

at 65°C for 30 seconds and primer extension at 70°C for 7 minutes.

SSCP was carried out with a Hoefer MiniVE vertical electrophoresis system. Two $\mu l$ of PCR-amplified DNA product was mixed with 2 $\mu l$ of formamide-loading dye solution. The mixture was denatured at 95°C for 5 minutes and cooled rapidly at 4°C before loading onto a 12% non-denaturing polyacrylamide gel (0.1x10x10 cm) in 1xTBE buffer (pH 8.0). Electrophoresis was carried out at 25°C, 90 V for 4 hours. The gel was stained using the silver staining method (Bassam et al, 1991).

Statistical analyses

Statistical analysis was performed using SPSS for Windows, version 9. Pearson chi-square ($\chi^2$) test was used to analyze differences in the frequencies of APOE genotypes in AD patients, non-AD demented patients and age-matched controls.

RESULTS

Clinical characteristics including age and sex distribution of patients with AD, non-AD dementia and aged-matched controls are summarized in Table 1. The mean age of all groups does not differ significantly. Thirty percent of patients had onset of the disease after the age of 60. The PCR-SSCP gel system provided results within 8 hours. The APOE polymorphism patterns of PCR products were silver-stained on 12% non-denaturing polyacrylamide gel. The DNA fragments showed different migration patterns among the alleles coded by $\varepsilon 2$, $\varepsilon 3$ and $\varepsilon 4$ (Fig 1) as previously described by Tsai et al (1993). The fragment...
coded by ε3 allele moved fastest, followed by that of ε2 and the DNA of ε4 allele. We detected that the APOE ε3/ε3 was the most common genotype in all groups followed by ε3/ε4, ε4/ε4 and ε2/ε3, respectively (Table 1). The frequency of APOE ε4 allele was significantly higher in AD patients (33.3%) than in age-matched controls (13.3%) ($\chi^2 = 10.43; p = 0.001$) and in non-AD dementia (10%) ($\chi^2 = 13.02; p < 0.001$) which was mainly due to an increase of APOE ε4 homozygotes. The frequency of APOE ε3 was significantly lower in AD patients (66.7%) than in age-matched controls (85.7%) ($\chi^2 = 10.68; p = 0.002$) and in non-AD dementia (90%) ($\chi^2 = 14.53; p < 0.001$).

DISCUSSION

Our study showed significant differences in APOE ε3 and ε4 allele frequencies between AD and other groups including non-AD dementia and age-matched controls. The APOE ε4 allele frequency in the AD group and in the control group was similar to those of published clinical series (Gomez-Isla et al, 1996; Saunders et al, 1996) and showed the expected increase in ε4 allele frequency associated with AD. In addition, homozygosity for the ε4 was found only in patients with AD. Furthermore, the ε4 allele distribution in the control group showed no differences from that of the non-AD dementia. This raises the possibility that unrecognized cases of AD exist among the non-AD dementia. Our findings confirmed that APOE ε4 allele is a genetic risk factor for AD which is consistent with previous studies (Senanarong et al, 2001; Liu et al, 1995; Fabian et al, 1996; Kakulas and van Bockxmeer, 1996; Kuo et al, 2003). We observed a protective effect of the ε2 allele but it was limited to the ε2/ε3 genotype which was detected only in the control group. These data confirm previous reports (Saunders et al, 1996; Farrer et al, 1997) showing that the ε2/ε3 genotype is associated with a lower risk of AD. It is noteworthy that none of the subjects are homozygous for the ε2 allele. Similarly, Farrer et al (1997) reported that the influence of the rare ε2/ε2 genotype on AD risk could not be discerned even in a very large sample.

We demonstrated the feasibility of using PCR-SSCP to distinguish the genotypes of APOE polymorphism. This method avoids the need for restriction enzyme digestion and possible problems with incomplete cleavage (Tsai et al, 1993; Aozaki et al, 1994; Wilton and Lim, 1995) Moreover, the APOE genotype in DNA extracted from the blood can be identified within 8 hours. Our method is faster than PCR-RFLP, which needs at least 6 hours for the restriction-enzyme digestion step (Zivelin et al, 1997; Riemenschneider et al, 2002).

ACKNOWLEDGEMENTS

This work was supported in part by the University Development Commission (UDC) scholarship. We thank Prof BA Baldwin for proof-reading the manuscript and Ms Wannee Pongsuwan for her technical assistance.

REFERENCES


RAPID DETECTION OF APOLIPOPROTEIN E GENOTYPES IN ALZHEIMER’S DISEASE

Corder EH, Sounder AM, Stritmatter WJ. Gene
dose of apolipoprotein E ε4 allele and the risk
of Alzheimer’s disease in late-onset families.

Corder EH, Ghebremedhin E, Taylor MG, Thai DR,
Ohm TG, Braak H. The biphasic relationship
between regional brain senile plaques and
neurofibrillary tangle distributions: modification
by age, sex, and APOE polymorphism. Ann NY

Fabian VA, J ones TM, Wilton SD, et al. Alzheimer’s
disease and apolipoprotein E genotype in
Western Australia: an autopsy-verified series.

Farrer LA, Cupples AL, Haines J L, et al. Effects of
age, sex, and ethnicity on the association
between apolipoprotein E genotype and
Inform Assoc 1997; 278: 1949-56.

Gomez-Isla T, West HI, Rebeck W, et al. Clinical and
pathological correlates of apolipoprotein E ε4
62-70.

Hardy J. Amyloid, the presenilins and Alzheimer’s

Hayashi K, Yandell DW. How sensitive is PCR-

Hixson JE, Verneir D. Restriction isotyping of human
apolipoprotein E be gene amplification and

Kakulas BA, van Bockxmeer F. Apolipoprotein E
genotyping in the diagnosis of Alzheimer’s dis-
ease: a cautionary view. Ann Neurol 1996; 38:
966-7.

Kontula K, Aalto-Setala K, Kuusl T, Hammadainen
L, Syvanen AC. Apolipoprotein E polymor-
phism determined by restriction enzyme analy-
sis of DNA amplified by polymerase chain re-
ation: convenient alternative to phenotyping
by isoelectric focusing. Clin Chem 1990; 36:
2087-92.

between interleukin -1α polymorphism and
Alzheimer’s disease or vascular dementia. Alz

Liu HC, Lin KN, Teng EL, et al. Prevalence and sub-
jects of dementia in Taiwan a community sur-

Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and
sensitive detection of point mutations and
DNA polymorphisms using the polymerase

Parker RG, Cathcart HM, Huang R, Lanham IS,
Corder EH, Poduslo RE. Apolipoprotein gene
E4 allele promoter polymorphisms as risk fac-
tors for Alzheimer’s disease. Psychiatr Genet

Price DL, Sisodia SS, Borchelt DR. Alzheimer dis-
ease: when and why? Nat Genet 1998; 19:
314-6.

Riemenschneider M, Diehl J, Miller U, Forstl H, Kurz
A. Apolipoprotein E polymorphism in German
patients with frontotemporal degeneration. J
Neurol Neurosurg Psychiatry 2002; 72: 639-
41.

Saunders AM, Strittmatter WJ, Schmechel D, et al.
Association of apolipoprotein E allele epsilon
4 with late-onset familial and sporadic
Alzheimer’s disease. Neurology 1993; 43:
1467-72.

Saunders AM, Hulette C, Welsh-Bohmer KA, et al.
Specificity, sensitivity, and predictive value of
apolipoprotein E genotyping for sporadic
Alzheimer’s disease. Neurology 1993; 43:
1467-72.

Experience of ApoE study in Thai elderly. J

Tsai MY, Suess P, Sch witthenburg K. Determination
of apolipoprotein E genotypes by Single-
Strand Conformational Polymorphism. Clin

Wilton S, Lim L. Rapid identification of APOE alle-
les by multiple-single strand conformation
polymorphism (SSCP) analysis. Trends Genet

method for genotyping apolipoprotein E poly-
morphisms by a PCR-based assay simulta-
neously utilizing two distinct restriction en-